Pharmacyte Biotech Inc (OTCMKTS:PMCB) And Growblox Sciences Inc (OTCMKTS:GBLX) Trades In A Narrow Range

Pharmacyte Biotech Inc (OTCMKTS:PMCB) declined 0.52% and closed at $0.0959 in last trading session. The biotech firm is still in clinical stage and it is working to develop targeted therapies to treat diabetes and cancer based on Cell-in-a-Box® technology. Recently, the COO of Pharmacyte, Dr. Gerald W. Crabtree, Ph.D. highlighted company’s development plans in an interview featured in ‘PharmaVOICE Magazine’.

Dr. Crabtree stated that that the company has engaged leading expert team for the advancement of advanced therapies. The expert team will help company to move forward with the planned clinical development trials. This interview with PharmaVOICE magazine worked as an opportunity for the management to highlight the development plans and reason behind deploying the expert team.

Growblox Sciences Inc (OTCMKTS:GBLX) a BioPharma firm with state-of-the-art technologies in plant biology developed to cultivate medicinal cannabis, stated that the company engaged Mr. John Poss as the new CFO. Craig Ellins, the CEO expressed that the performance of Poss as a consultant in the company encouraged them to take this decision.

The decision boosts company’s plan to move from the engineering intensive development phase to the regular operations of cultivating an excellent product, and improving revenue. Growblox team believes that Poss will play a key role in helping the company to move through transition phase expeditiously and smoothly. Expressing his views, Mr. Poss stated that he is delighted to be a part of Growblox. As a cancer survivor, he strongly believes in the medicinal value of marijuana to treat many fatal diseases.

In last trading session, the stock price of Growblox consolidated and closed at $0.285.

Sangamo Biosciences, Inc. (NASDAQ:SGMO) Updates On Clinical Plans

Sangamo Biosciences, Inc. (NASDAQ:SGMO) stated that they have agreed to extend collaboration and license contract with Shire PLC (ADR) (NASDAQ:SHPG) to accelerate the development of ZFP Therapeutics for cure of Huntington’s and Hemophilia ‘A’ and ‘B’ disease.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact ir@edm.media.

Published by Nicholas Maithya

Nicholas is a Financial Analyst by profession, who enjoys writing about investments, technological developments, business, economics and other financial topics at various financial publications. Join him here on Wallstreetpr.com as he endeavors to deliver to you the latest breaking news on the above mentioned fronts. Contact him by email at nmaithya@gmail.com or follow Nicholas Kitonyi @nmaithyak on Twitter.

Recent Stories

SignUp Now For Our Featured Newsletter